DDInter1771 DDInter1341
Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of hepatoxicity and teratogenicity for patients using teriflunomide.
Onasemnogene abeparvovec is an adeno-associated virus vector-based gene therapy that has been approved by the FDA in May 2019 for the treatment of infant patients (less than 2 years of age) with spinal muscular atrophy (SMA) and a specific mutation in the survival motor neuron 1 (SMN1) gene. SMA is a rare genetic disease that affects the survival and function of motor neurons, leading to debilitating and often fatal muscle weakness. As there is no cure for SMA, onasemnogene abeparvovec is a disease-modifying agent that decelerates the disease progression, improves motor function, and manages the symptoms. The use and effectiveness of onasemnogene abeparvovec in patients with advanced SMA, such as those with complete paralysis of the limbs and permanent dependence on ventilators, has not been evaluated. Onasemnogene abeparvovec is the first gene therapy that was approved for this indication in the USA. [Nusinersen] is another gene therapy that is currently approved by the FDA for the treatment of SMA in pediatric and adult patients. Developed by AveXis, a Novartis company, onasemnogene abeparvovec is commonly marketed as Zolgensma®, which is available as a single-dose intravenous infusion. Onasemnogene abeparvovec for therapeutic use and marketing is currently being assessed by the EU and an intrathecal formulation of the drug is currently undergoing clinical development in the USA.
Teriflunomide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Teriflunomide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Teriflunomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enzalutamide
Teriflunomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Melatonin
Teriflunomide {u} may lead to a major life threatening interaction when taken with {v} Mephenytoin
Teriflunomide {u} may lead to a major life threatening interaction when taken with {v} Asparaginase Erwinia chrysanthemi
Teriflunomide may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Teriflunomide may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Melatonin
Teriflunomide may lead to a major life threatening interaction when taken with Mephenytoin
Teriflunomide may lead to a major life threatening interaction when taken with Asparaginase Erwinia chrysanthemi